This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dendreon's Blowup Spreads Across Biotech

Stocks in this article: HGSI ITMN SGEN SVNT REGN CLSN BCRX

BOSTON ( TheStreet) -- The Dendreon (DNDN) flu is contaminating the entire biotech sector. The Nasdaq Biotechnology Index (NBI) slumped more than 4% Thursday amidst broader market selling as biotech investors react in panic to last night's surprise disclosure by Dendreon that sales of its prostate cancer drug Provenge are growing much slower than expected.

Dendreon is taking the brunt of the pain, down $23.06, or 64%, to $12.78, but other biotech stocks, particularly those with drug launches commenced or soon to start, are also getting "Provenged."

Human Genome Sciences (HGSI), which just launched the Benlysta lupus drug, is down $1.59, or 9%, to $16.47. Intermune (ITMN), readying a European launch of a lung disease drug, is down down $3.23, or 10%, to $28.01. Other "drug launch" stocks in similar situations like Seattle Genetics (SGEN), Regeneron Pharmaceuticals (REGN) and Savient Pharmaceuticals (SVNT), are also getting hit.

Dendreon's blow up could not have come at a worse time for the biotech sector. Investors already wary about investing in new biotech drug launches are now even more scared or skeptical. The overall market is on shaky ground and concerns about new cuts to Medicare have re-surfaced in the wake of the debt ceiling and budget battles in Washington.

If the Nasdaq Biotechnology Index falls below 970, it will go red for the year.

Likely contributing to the weakness in biotech Thursday is the fact that many investors who were long Dendreon going into last night are now being forced to sell other biotech holdings to make up for heavy loss. It remains to be seen whether opportunistic buyers step in to pick up stocks oversold on the Dendreon selling.

SAC Capital, run by renowned hedge fund manager Steve Cohen, is (or was) Dendreon's largest shareholder. On paper, SAC lost around $180 million when Dendreon tanked Thursday.

Early stage biotechs aren't being spared, with stocks likes Celsion (CLSN)down 12% and Biocryst Pharmaceuticals (BCRX) falling 18%.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs